MedTrace Logo

A Study of Lu AF82422 in Participants With Multiple System Atrophy

NCT05104476 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-04-13

Study results available
· View outcomes & findings →

Summary

To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.

Conditions

Interventions

DRUG

Lu AF82422

Solution for infusion

DRUG

Placebo

Solution for infusion

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

  • Email contact via H. Lundbeck A/S · H. Lundbeck A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-16
Primary Completion
2023-11-16
Completion
2028-03-07
FDA Drug
Yes

Countries

  • United States
  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05104476 on ClinicalTrials.gov